Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 15/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | SCN7A | Q01118 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28356469 | 0.89 | MAPK1 (0.47) | SCN9AMAPK1LMNATHRBSCN10A | |
| SCHEMBL28353221 | 0.81 | SCN9A (0.50) | SCN9AMAPK1SCN7AKCNH2SCN10A | |
| SCHEMBL28356466 | 0.81 | SCN9A (0.48) | SCN9AMAPK1LMNATHRBSCN10A | |
| SCHEMBL24116804 | 0.81 | MAOB (0.51) | SCN9AMAPK1LMNATHRBSCN7A | |
| SCHEMBL18638520 | 0.76 | SCN9A (0.52) | SCN9AMAPK1SCN7AKCNH2SCN10A | |
| SCHEMBL29463828 | 0.76 | SCN9A (0.52) | SCN9AMAPK1SCN7AKCNH2SCN10A | |
| SCHEMBL29463817 | 0.73 | SCN9A (0.54) | SCN9AMAPK1SCN7AKCNH2SCN10A | |
| SCHEMBL18638315 | 0.73 | SCN9A (0.54) | SCN9AMAPK1SCN7AKCNH2SCN10A | |
| SCHEMBL29463882 | 0.70 | SCN9A (0.48) | SCN9AMAPK1THRBSCN7AKCNH2 | |
| SCHEMBL18638454 | 0.70 | SCN9A (0.48) | SCN9AMAPK1THRBSCN7AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110612290-A | Novel benzimidazolone compounds and medicinal use thereof | 大日本住友制药株式会社 | 2019-12-24 | — | — | CN | claimed |
| US-20210393604-A1 | NOVEL BENZIMIDAZOLONE COMPOUND AND PHARMACEUTICAL USE THEREOF | Sumitomo Pharma Co., Ltd. (JP) | 2021-12-23 | — | — | US | disclosed |
| CN-110612290-A | Novel benzimidazolone compounds and medicinal use thereof | 大日本住友制药株式会社 | 2019-12-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393604-A1 | NOVEL BENZIMIDAZOLONE COMPOUND AND PHARMACEUTICAL USE THEREOF | HCN4, CACNA1E, SCN1B | SCN9A 55/4885MAPK1 205/4885LMNA 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.